Search

Your search keyword '"Langford, Paul R."' showing total 5 results
Start Over Author "Langford, Paul R." Journal vaccine
5 results on '"Langford, Paul R."'

5. Population-based analysis of Actinobacillus pleuropneumoniae ApxIVA for use as a DIVA antigen.

Author

O'Neilla C, Jones SCP, Bossé JT, Watson CM, Williamson SM, Rycroft AN, Simon Kroll J, Hartley HM, and Langford PR

Subjects
Actinobacillus Infections immunology, Actinobacillus Infections prevention & control, Actinobacillus pleuropneumoniae immunology, Actinobacillus pleuropneumoniae isolation & purification, Animals, Antigens, Bacterial genetics, Bacterial Proteins genetics, DNA, Bacterial genetics, England, Mutagenesis, Insertional, Mutation, Polymerase Chain Reaction, Sequence Analysis, DNA, Wales, Actinobacillus pleuropneumoniae genetics, Antigens, Bacterial immunology, Bacterial Proteins immunology
Abstract

APXIVA is an RTX toxin of Actinobacillus pleuropneumoniae that is a candidate antigen to differentiate infected from vaccinated animals (DIVA). Insertion of ISApl1 into the apxIVA gene is known to compromise an APXIVA-based DIVA approach, as is potentially a TGG to TGA mutation in the apxIVA gene. ISApl1 was found in 63/349 (18.1%) A. pleuropneumoniae isolates from England and Wales including serovars 2, 3, 6-8 and 12. No ISApl1 insertions into apxIVA were found. Only two serovar 3 isolates contained the TGG to TGA mutation. We conclude that an ApxIVA-based DIVA approach would potentially be viable in England and Wales., (Copyright 2010 Elsevier Ltd. All rights reserved.)

Published
2010
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results